SINGAPORE INKS MOU WITH QUANTINUUM, ENABLING ACCESS TO THEIR ADVANCED QUANTUM COMPUTER

SINGAPORE, July 23, 2024 /CNW/ -- Singapore's National Quantum Office (NQO), Agency for Science, Technology and Research (A*STAR), National University of Singapore (NUS), National Supercomputing Centre (NSCC) and Quantinuum signed a Memorandum of Understanding (MoU) today, enabling access to Quantinuum's advanced quantum computer, and to explore and collaborate on quantum computing use cases, focusing on computational biology.

[From left to right, seated] The MoU signing was represented by Dr Su Yi, Executive Director, A*STAR’s Institute of High Performance Computing; Mr Ling Keok Tong, Executive Director, National Quantum Office; Prof José Ignacio Latorre, Director, Centre for Quantum Technologies; Dr Raj Hazra, President & CEO, Quantinuum, Dr Sebastian Maurer-Stroh, Executive Director, A*STAR’s Bioinformatics Institute; Prof Thomas M. Coffman, Dean, Duke-NUS Medical School; Dr Terence Hung, Chief Executive, National Supercomputing Centre Singapore. 
[From left to right, standing] The MoU signing was witnessed by Prof Tan Sze Wee, Assistant Chief Executive, Biomedical Research Council, A*STAR; Prof Yeo Yee Chia, Assistant Chief Executive, Innovation & Enterprise, A*STAR; Prof Low Teck Seng, Co-chair, National Quantum Steering Committee; Mr Quek Gim Pew, Co-chair, National Quantum Steering Committee; Mr Ilyas Khan, Founder & Chief Product Officer, Quantinuum
[From left to right, seated] The MoU signing was represented by Dr Su Yi, Executive Director, A*STAR’s Institute of High Performance Computing; Mr Ling Keok Tong, Executive Director, National Quantum Office; Prof José Ignacio Latorre, Director, Centre for Quantum Technologies; Dr Raj Hazra, President & CEO, Quantinuum, Dr Sebastian Maurer-Stroh, Executive Director, A*STAR’s Bioinformatics Institute; Prof Thomas M. Coffman, Dean, Duke-NUS Medical School; Dr Terence Hung, Chief Executive, National Supercomputing Centre Singapore. [From left to right, standing] The MoU signing was witnessed by Prof Tan Sze Wee, Assistant Chief Executive, Biomedical Research Council, A*STAR; Prof Yeo Yee Chia, Assistant Chief Executive, Innovation & Enterprise, A*STAR; Prof Low Teck Seng, Co-chair, National Quantum Steering Committee; Mr Quek Gim Pew, Co-chair, National Quantum Steering Committee; Mr Ilyas Khan, Founder & Chief Product Officer, Quantinuum

Under the MoU, the parties agree to leverage Quantinuum's H-Series and Helios quantum computers, to promote joint research and development (R&D) activities in various quantum computing applications. Helios is Quantinuum's next generation quantum processor that could exponentially increase the computing power of quantum computers.

The parties will also collaborate on developing hybrid computing solutions that include both classical and quantum computing infrastructures, leading to the creation of long-term strategic roadmaps. The MoU also enables collaborations in training and outreach through seminars, workshops and bespoke programmes to nurture quantum talent and contribute towards Singapore's growing quantum community.

Singapore has a strong background in computational biology and the collection of quality health datasets. Through this MoU, scientists from A*STAR's Bioinformatics Institute (A*STAR's BII), the Centre for Quantum Technologies (CQT) at NUS and Duke-NUS Medical School's Centre for Computational Biology will be able to leverage Quantinuum's machines to enhance capabilities in modelling complex biological systems, advancing drug discovery and personalised medicine. In addition, Quantinuum also plans to establish a dedicated R&D presence in Singapore, where researchers from both Quantinuum and Singapore could better exchange knowledge and expertise for further developments in quantum applications and algorithms.

As the largest quantum computing company that has demonstrated success in building the highest performing quantum computers, Quantinuum offers an integrated, end-to-end quantum computing platform. Quantinuum leverages trapped-ion technology – one of the most promising approaches for building the highest fidelity and scalable quantum computers - to develop use cases in a wide range of applications, including pharmaceuticals, material sciences, and finance.

This MoU is guided by Singapore's National Quantum Strategy, which aims to strengthen Singapore's position as a leading hub in the development and deployment of quantum technologies by bolstering scientific excellence in high impact areas of quantum research; strengthening Singapore's engineering capabilities in quantum technologies to accelerate translation into real world solutions; attracting, developing and retaining quantum talent; and anchoring company partnerships to build a vibrant and resilient quantum industry.